Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Aug 24, 2023 3:54pm
211 Views
Post# 35604270

Table format of the state of the landscape

Table format of the state of the landscape
For interest in a table format. Enrique, Eog and others feel free to correct the error as I'm sure there are some.

Drug FDA status 3 M CR 12 M CR Route of administration Number of treatments
Vicinium FDA rejected 42% 17% bladder instillation 36 instills per year
Keytrude Approved 41% 19% intravenous every 3 weeks (indefinitely?)
Atezolizumab Likely stalled 43% 20% bladder instillation every 3 week for 1 yr
Adstiladrin Approved 53% 24% bladder instillation every 3 months for first year then after (?)
Oportuzumab monatox not-approved 40% 17% intravenous 15 treatment in a year approx but varies
n-803 + BCG Approval deferred for now 55% 44% bladder instillation 15 treatment in a year approx but varies
Valrubicin Approved but not used (?) 21% 8% bladder instillation 6 weekly as induction and that is all
           
Ruvidar Phase 2 ongoing 66% 36% bladder instillation 2 total

<< Previous
Bullboard Posts
Next >>